D.E. Shaw & Co
BEAM icon

D.E. Shaw & Co’s Beam Therapeutics BEAM Stock Holding History

D.E. Shaw & Co’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,935
Closed -$774K – 4546
2025
Q4 		$774K Buy
+27,935
New +$713K ﹤0.01% 3694
2024
Q3 		– Sell
-8,721
Closed -$204K – 4532
2024
Q2 		$204K Buy
+8,721
New +$214K ﹤0.01% 4065
2022
Q4 		– Sell
-43,995
Closed -$2.1M – 4863
2022
Q3 		$2.1M Buy
+43,995
New +$2.51M ﹤0.01% 2965
2022
Q1 		– Sell
-17,269
Closed -$1.38M – 5530
2021
Q4 		$1.38M Sell
17,269
-41,974
-71% -$3.59M ﹤0.01% 3672
2021
Q3 		$5.16M Buy
+59,243
New +$5.95M ﹤0.01% 2077
2021
Q2 		– Sell
-6,196
Closed -$494K – 4748
2021
Q1 		$496K Buy
+6,196
New +$589K ﹤0.01% 3508

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

D.E. Shaw & Co's BEAM Position: Q1 2026 in Review

D.E. Shaw & Co sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 27,935 shares — an estimated $774K sold.

D.E. Shaw & Co first reported a position in BEAM in Q1 2021 and held it in 6 quarters. The position peaked at $5.16M in Q3 2021. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • D.E. Shaw & Co reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • D.E. Shaw & Co sold 27,935 Beam Therapeutics shares in Q1 2026, an estimated $774K.
  • D.E. Shaw & Co first reported a position in Beam Therapeutics in Q1 2021 and held it in 6 quarters.
  • D.E. Shaw & Co's Beam Therapeutics position peaked at $5.16M in Q3 2021.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.